27 Nov 20 - AstraZeneca’s Error | Argosy Update Global markets were mixed in very quiet trade overnight as the US markets were closed for Thanksgiving holiday. Overnight there has been negative vaccine news. The AstraZeneca vaccine developed in conjunction with Oxford University will be studied with a new trial, after reports that the apparent effectiveness followed a manufacturing error – where the vaccine was found to be more effective (90%) with an initial half dose manufactured in error, used in a sample of a younger group of participants. The lower rate of effectiveness (62%) when the vaccine was applied with two full doses was achieved in a group included participants aged over 55.   Argosy Property (ARG:NZX) Shares in Argosy were higher yesterday as a better than expected outcome out of COVID saw Argosy modestly raise its dividend.  We continue to remain BUY rated on relative valuation support and now see ARG as our top property sector pick....